Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.34 |
| ▸ | TSHR | P16473 | 3/20 | 0.33 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.32 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.31 |
| ▸ | POLE3 | Q9NRF9 | 1/20 | 0.31 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7666958 | 1.00 | MEN1 (0.47) | MEN1ALDH1A1KMT2ATGFBR1LMNA | |
| SCHEMBL30597491 | 0.83 | MEN1 (0.49) | MEN1ALDH1A1KMT2ATGFBR1LMNA | |
| SCHEMBL1244477 | 0.81 | MEN1 (0.47) | MEN1ALDH1A1KMT2ATGFBR1LMNA | |
| SCHEMBL21673038 | 0.81 | MEN1 (0.47) | MEN1ALDH1A1KMT2ATGFBR1LMNA | |
| SCHEMBL8330697 | 0.74 | ALDH1A1 (0.41) | MEN1ALDH1A1KMT2ATGFBR1LMNA | |
| SCHEMBL20969207 | 0.73 | MEN1 (0.40) | MEN1ALDH1A1KMT2ATGFBR1NFE2L2 | |
| SCHEMBL7700637 | 0.73 | TSHR (0.40) | MEN1ALDH1A1KMT2ATGFBR1TSHR | |
| SCHEMBL20969489 | 0.72 | ALDH1A1 (0.39) | MEN1ALDH1A1KMT2ATGFBR1TSHR | |
| SCHEMBL20969493 | 0.72 | ALDH1A1 (0.39) | MEN1ALDH1A1KMT2ATGFBR1TSHR | |
| SCHEMBL32678441 | 0.71 | PTPN11 (0.36) | MEN1ALDH1A1KMT2APTPN11POLE3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1620381-A1 | HYDROANTHRACENE BASED COMPOUNDS AS ANTICANCER AGENTS | Dabur Research Foundation (IN) | 2006-02-01 | — | — | EP | disclosed |
| US-6949557-B2 | Hydroanthracene based compounds as anticancer agents | DABUR RESEARCH FOUNDATION (IN) | 2005-09-27 | — | — | US | disclosed |
| WO-2004096742-A1 | HYDROANTHRACENE BASED COMPOUNDS AS ANTICANCER AGENTS | DABUR RESEARCH FOUNDATION (IN) | 2004-11-11 | — | — | WO | disclosed |
| US-20040220197-A1 | Hydroanthracene based compounds as anticancer agents | DABUR RESEARCH FOUNDATION | 2004-11-04 | — | — | US | disclosed |
| US-6051590-A | USEFUL AS POTASSIUM CHANNEL INHIBITORS TO TREAT AUTOIMMUNE DISORDERS | MERCK & CO., INC. (US) | 2000-04-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040220197-A1 | Hydroanthracene based compounds as anticancer agents | MCL1, TP53, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | MEN1 463/4885ALDH1A1 1238/4885KMT2A 2461/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.